Edesa Biotech Inc's Comment on Sales, Marketing and Customers
The company intends to commercialize investigational medicines in the U.S., Canada, and Europe through its own sales force or by outsourcing sales and marketing. It also plans to engage in strategic licensing, collaboration, distribution, or other marketing arrangements with third parties, particularly outside North America. Its product candidates include EB01 and EB05, with potential future products targeting vitiligo and fibrotic diseases. The company’s market segments encompass therapies for SARS-CoV-2 and influenza viruses, stem cell therapies, novel therapeutics, and repurposed commercial drugs. Competitors include large pharmaceutical and smaller biotechnology companies with greater resources. Success factors include efficacy, safety, drug interactions, administration method, pricing, reimbursement, and promotional activity.
Customers and markets referenced include Aclaris Therapeutics, Inc., Aqualung Therapeutics Corporation, Astria Therapeutics, Inc., Bausch Health, Boehringer Ingelheim AG, Chemomab Therapeutics Ltd., Dermavant Sciences, Inc., Eli Lilly and Company, Enzychem Lifesciences Corp., F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Incyte Corporation, InflaRx N.V., Leo Pharma A/S, Merck & Co., Inc., Mesoblast Limited, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., UCB, Veru Inc., and Vyne Therapeutics Inc.
Edesa Biotech Inc’s Comment on Sales, Marketing and Customers
The company intends to commercialize investigational medicines in the U.S., Canada, and Europe through its own sales force or by outsourcing sales and marketing. It also plans to engage in strategic licensing, collaboration, distribution, or other marketing arrangements with third parties, particularly outside North America. Its product candidates include EB01 and EB05, with potential future products targeting vitiligo and fibrotic diseases. The company’s market segments encompass therapies for SARS-CoV-2 and influenza viruses, stem cell therapies, novel therapeutics, and repurposed commercial drugs. Competitors include large pharmaceutical and smaller biotechnology companies with greater resources. Success factors include efficacy, safety, drug interactions, administration method, pricing, reimbursement, and promotional activity.
Customers and markets referenced include Aclaris Therapeutics, Inc., Aqualung Therapeutics Corporation, Astria Therapeutics, Inc., Bausch Health, Boehringer Ingelheim AG, Chemomab Therapeutics Ltd., Dermavant Sciences, Inc., Eli Lilly and Company, Enzychem Lifesciences Corp., F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Incyte Corporation, InflaRx N.V., Leo Pharma A/S, Merck & Co., Inc., Mesoblast Limited, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., UCB, Veru Inc., and Vyne Therapeutics Inc.
Sources:
Edesa Biotech Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Edesa Biotech Inc’s corporate clients.
For your research, we’ve provided 9 tables on Edesa Biotech Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
